These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28700479)

  • 41. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?
    Jarrin I; Pantazis N; Dalmau J; Phillips AN; Olson A; Mussini C; Boufassa F; Costagliola D; Porter K; Blanco J; Del Amo J; Martinez-Picado J;
    AIDS; 2015 Nov; 29(17):2323-33. PubMed ID: 26544704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High Current CD4+ T Cell Count Predicts Suboptimal Adherence to Antiretroviral Therapy.
    Pasternak AO; de Bruin M; Bakker M; Berkhout B; Prins JM
    PLoS One; 2015; 10(10):e0140791. PubMed ID: 26468956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIV-1 infection: results from a longitudinal study in the French ANRS Primo cohort.
    Novelli S; Delobel P; Bouchaud O; Avettand-Fenoel V; Fialaire P; Cabié A; Souala F; Raffi F; Catalan P; Weiss L; Meyer L; Goujard C
    J Int AIDS Soc; 2020 Apr; 23(4):e25485. PubMed ID: 32333726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.
    Routy JP; Angel JB; Patel M; Kanagaratham C; Radzioch D; Kema I; Gilmore N; Ancuta P; Singer J; Jenabian MA
    HIV Med; 2015 Jan; 16(1):48-56. PubMed ID: 24889179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD4+ T-cell Count may not be a Useful Strategy to Monitor Antiretroviral Therapy Response in HTLV-1/HIV Co-infected Patients.
    Vandormael A; Rego F; Danaviah S; Carlos Junior Alcantara L; Boulware DR; de Oliveira T
    Curr HIV Res; 2017; 15(3):225-231. PubMed ID: 28215175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recovery of effective HIV-specific CD4+ T-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia.
    Adland E; Mori L; Laker L; Csala A; Muenchhoff M; Swordy A; Mori M; Matthews P; Tudor-Williams G; Jooste P; Goulder P
    AIDS; 2018 Jul; 32(11):1413-1422. PubMed ID: 29734220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Associations of gender and serum total cholesterol with CD4+ T cell count and HIV RNA load in antiretroviral-naïve individuals in Addis Ababa.
    Adal M; Howe R; Kassa D; Aseffa A; Petros B
    BMC Public Health; 2018 Jul; 18(1):943. PubMed ID: 30064395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Composition of Gut Microbiota of Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection Taking Antiretroviral Therapy in Zimbabwe.
    Flygel TT; Sovershaeva E; Claassen-Weitz S; Hjerde E; Mwaikono KS; Odland JØ; Ferrand RA; Mchugh G; Gutteberg TJ; Nicol MP; Cavanagh JP; Flægstad T;
    J Infect Dis; 2020 Jan; 221(3):483-492. PubMed ID: 31549151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis.
    Tan DB; Yong YK; Tan HY; Kamarulzaman A; Tan LH; Lim A; James I; French M; Price P
    HIV Med; 2008 May; 9(5):307-16. PubMed ID: 18400078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection.
    Ofotokun I; Titanji K; Vunnava A; Roser-Page S; Vikulina T; Villinger F; Rogers K; Sheth AN; Lahiri CD; Lennox JL; Weitzmann MN
    AIDS; 2016 Jan; 30(3):405-14. PubMed ID: 26760232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Finlayson R; Zaunders J; Smith D; Cooper DA
    AIDS; 2002 Feb; 16(3):359-67. PubMed ID: 11834947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune signatures for HIV-1 and HIV-2 induced CD4
    Salwe S; Singh A; Padwal V; Velhal S; Nagar V; Patil P; Deshpande A; Patel V
    BMC Infect Dis; 2019 Feb; 19(1):135. PubMed ID: 30744575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiretroviral therapy-induced dominant interleukin-2 HIV-1 Gag CD4+ T cell response: evidence of functional recovery of HIV-1-specific CD4+ T cells.
    Tsalimalma K; Kordossis T; Choremi-Papadopoulou E
    Scand J Immunol; 2011 Mar; 73(3):256-65. PubMed ID: 21204901
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
    Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
    AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thymic Function as a Predictor of Immune Recovery in Chronically HIV-Infected Patients Initiating Antiretroviral Therapy.
    Rb-Silva R; Nobrega C; Azevedo C; Athayde E; Canto-Gomes J; Ferreira I; Cheynier R; Yates AJ; Horta A; Correia-Neves M
    Front Immunol; 2019; 10():25. PubMed ID: 30804925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.
    Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D;
    AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Zero CD4 count: a case of discordant CD4 response in a patient with well suppressed viral load.
    Raja K; Chandrasekar C; Krishnarajasekhar OR; Manoharan G
    Indian J Med Microbiol; 2013; 31(3):298-302. PubMed ID: 23883722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.